CTOs on the Move

Verseon

www.verseon.com

 
Verseon is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.verseon.com
  • 48371 Fremont Blvd Ste 101
    Fremont, CA USA 94538
  • Phone: 510.225.9000

Executives

Name Title Contact Details

Similar Companies

Enzymerx

Enzymerx is a Paramus, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ArrePath

ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies.

Cardea

Cardeas BPU™ (Biosignal Processing Unit) is a biocompatible semiconductor capable of translating real-time streams of multiomics signals to digital information

Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical corporation based in Indianapolis, Indiana, with a history of nearly 150 years. Founded in 1876 by Colonel Eli Lilly, the company has grown to become one of the largest pharmaceutical enterprises in the world, employing over 42,900 people as of 2023. Lilly focuses on biomedical research, drug discovery, and manufacturing, with a diverse portfolio that includes treatments for diabetes, oncology, neuroscience, and immunology. Lilly pioneered the first commercially available insulin product in 1923 and continues to innovate with modern offerings like Trulicity and Mounjaro for diabetes management. The company also develops drugs such as Verzenio for breast cancer and Zyprexa for psychiatric disorders. With a strong emphasis on research and development, Lilly is recognized for its commitment to improving drug accessibility and patient care through partnerships with healthcare providers and systems worldwide.

Imvax

The approach is an autologous, cell-based treatment that activates the full array of patient-specific antigens, resulting in both an innate and adaptive immune response. The company`s lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer with a significant unmet need. In parallel, the company is also progressing the platform in a select number of additional solid tumors where the unmet need remains great and where initial immunotherapy approaches have often failed to provide a significant benefit.